Celltech Group plc Announces Initiation of CDP870 Phase III Trials in Crohn's Disease
06 janv. 2004 02h03 HE
|
Celltech Group plc
SLOUGH, U.K., Jan. 5, 2004 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) today announces that it commenced dosing of patients in the first of two pivotal Phase III studies ("PRECISE-1") for...
Celltech Group Plc announces Holding(s) in Company
10 déc. 2003 05h47 HE
|
Celltech Group plc
Slough, U.K., Dec. 10, 2003 (PRIMEZONE) -- Celltech Group Plc:
SCHEDULE 10
NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Name of company
Celltech Group plc
2. Name of shareholder having a...
Celltech Regains Full Rights To CDP 870 from Pfizer
01 déc. 2003 03h02 HE
|
Celltech Group plc
LONDON, Dec. 01, 2003 (PRIMEZONE) -- lltech Group plc (LSE:CCH)(NYSE:CLL) today announces that it will regain full rights to CDP 870, its PEGylated anti-TNF-alpha antibody fragment, from Pfizer...
Celltech Appoints New Director of Development
01 déc. 2003 03h01 HE
|
Celltech Group plc
LONDON, Dec. 1, 2003 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) today announces the appointment of Dr. Grahaem Brown as Director of Development. Grahaem has over 20 years of drug...
Celltech Announces Completion of OGS Integration Process
19 nov. 2003 03h43 HE
|
Celltech Group plc
SLOUGH, UK, Nov. 19, 2003 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) announced today that it has completed its integration of Oxford GlycoSciences (OGS), which was acquired in May 2003....
Celltech Group plc -- Closure of Seattle Research Facility
19 nov. 2003 03h31 HE
|
Celltech Group plc
SLOUGH, U.K., Nov. 19, 2003 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) announced today a reorganisation of its R&D operations designed to rebalance resources between its research and...
Celltech Group plc -- Update on CDP 870 Clinical Development Programme
13 nov. 2003 07h14 HE
|
Celltech Group plc
SLOUGH, U.K., Nov. 13, 2003 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) today announced an update on the clinical development programme for CDP 870, its PEGylated anti-TNF-alpha antibody...
Celltech: Re. Licensing Deal
30 oct. 2003 03h39 HE
|
Celltech Group plc
SLOUGH, U.K., Oct. 30, 2003 (PRIMEZONE) -- Celltech Pharmaceuticals, a division of Celltech Group plc (LSE:CCH) (NYSE:CLL), announces that it has licensed European sales and marketing rights to Xyrem...
Celltech Achieves Milestone in Osteoporosis Collaboration with Amgen
28 oct. 2003 02h03 HE
|
Celltech Group plc
SLOUGH, U.K., Oct. 28, 2003 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) today announced the achievement of a milestone in its agreement with Amgen Inc. for the research, development and...
Celltech Group PLC Announces Merck Extends Development Period For PDE4 Collaboration With Celltech
24 sept. 2003 02h02 HE
|
Celltech Group plc
SLOUGH, UK, Sept. 24, 2003 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) announces that Merck & Co., Inc. (NYSE:MRK) (Pink Sheets:MCKIF) has exercised its option to extend the...